Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether 4-AP (Dalfampridine-ER, Ampyra) improves
walking ability and endurance in adult patients with Spinal muscular atrophy (SMA) Type 3
compared to placebo and whether the duration of treatment affects outcome.